Question
BCR-ABL tyrosine kinase inhibitor that is indicated in CML only for resistant cases of previous therapy with first-line drugs are
| A. |
Imatinib
|
| B. |
Dasatinib
|
| C. |
Nilotinib
|
| D. |
Bosutinib
|
Show Answer
[ads id=”53026″]
|
Correct Answer � D
Explanation
|
|
Ans.D. Bosutinib is approved in CML only for resistant and/or intolerant cases for previous therapy.
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.
Indication- Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy in adult patients.
Like this:
Like Loading...
